AstraZeneca halts phase III trial of ZIBOTENTAN in non-metastatic castrate resistant prostate cancer

Monday, 7 February 2011

Important notice for users

You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses  may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes